Study of ZZSW-01 for B-cell blood cancers that returned or didn't respond
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug called ZZSW-01 for people with certain B-cell blood cancers (like lymphoma or leukemia) that have come back or haven't gotten better after other treatments. It aims to see if the drug is safe and works against these cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your cancer must be a type of B-cell lymphoma or leukemia that has come back or hasn't responded to at least two prior treatments.
- You must have measurable disease: for lymphoma, a lymph node bigger than 15 mm; for leukemia, at least 5% cancer cells in your bone marrow.
- Your organ function (like kidneys, liver, blood counts, and lung oxygen) must be within acceptable ranges, and you can't have certain infections or other serious medical conditions.
- You must not have had certain prior treatments like stem cell transplants or certain immunotherapy within specific timeframes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new experimental medicine (SYS6055 injection) for people with B-cell blood cancers (leukemia or lymphoma) that have come back or not responded to standard treatments. The goal is to see if it is safe and how well it works against cancer cells that have the CD19 marker.
A trial testing an experimental drug (UBX-303061) for people with certain B-cell blood cancers (like CLL, DLBCL, or MCL) that have returned or not responded to at least two other treatments. The goal is to see if the drug is safe and works when other options are no longer available.
This trial tests a new medicine called WGb-0301, given by injection, for people with certain blood cancers (B-cell lymphoma or lymphocytic leukemia) that have come back or not improved with other treatments. The goal is to see if this drug can help control the cancer and what side effects it might cause.
This trial tests a new drug, JBZ-001, to see how safe it is for people with advanced solid tumors or certain types of lymphoma that have not improved with standard treatments. It's a first-in-human study, so participants will help doctors learn about the drug's side effects and the right dose.
This study tests a new therapy called RS001 for people with B-cell lymphoma or B-cell leukemia that has not gotten better or has returned after treatment. It targets a marker called CD19 on cancer cells, and the goal is to see if it can help control the cancer.
This trial tests a new oral drug called DZD8586 for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to previous treatment. The goal is to see if it can help control the disease.
Hear when a new Relapsed/Refractory B-cell Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.